A pre-specified subgroup analysis from the phase 3 ADVANCE OUTCOMES study showed that ralinepag reduced the risk of clinical worsening in patients with pulmonary arterial hypertension (PAH), ...

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Sept. 19, 2017 /PRNewswire/ -- Martine Rothblatt, Chairman and Chief Executive Officer of United Therapeutics Corporation (NASDAQ: UTHR) is ...

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced the world’s first transplant of a ...

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the United States District Court for the District of Delaware issued an opinion that finds Liquidia ...

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., June 5, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it has filed a lawsuit in the U.S. District Court ...

SILVER SPRING, Md., July 27 /PRNewswire-FirstCall/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced that it repurchased an aggregate of 766,666 ...

SILVER SPRING, Md., Dec. 23 /PRNewswire-FirstCall/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today the appointment of the Honorable Tommy G ...

SILVER SPRING, Md., July 25 /PRNewswire-FirstCall/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced it would release its second quarter 2006 ...

The long-term, pivotal, phase 3 ADVANCE OUTCOMES study met its primary endpoint, with ralinepag achieving a statistically significant 55% reduction in risk of clinical worsening in predominantly ...

ADVANCE OUTCOMES presentations include an analysis showing that ralinepag achieved clinical improvement in a lower risk pulmonary arterial hypertension (PAH) population and reduced clinical worsening ...

View source version on businesswire.com: https://www.businesswire.com/news/home/20260506844951/en/ ...